Planmed Clarity™ mammography system receives Health Canada approval

Report this content

Health Canada has issued an approval letter for the Planmed Clarity™ 2D digital mammography system and the Planmed Clarity™ 3D digital mammography tomosynthesis system on March 8, 2018. The Planmed Clarity system is a powerful tool for breast cancer screening and diagnostic follow-ups. The elegant system provides great image quality, optimal ergonomics, and excellent usability.

Managing Director of Planmed, Mr. Jan Moed, is excited to bring the system to the Canadian market: "We are extremely pleased to have received Health Canada’s medical license for our Planmed Clarity system. This is a great next step for this unique product family. And we got the approval on the International Women’s Day, no less. I can’t think of a better way to celebrate Women’s Day.”

Compared to 2D imaging, digital breast tomosynthesis produces a 3D volume of the breast and resolves the challenge of overlapping tissue structures resulting in enhanced diagnostics, especially for women with dense breast tissue.

“Breast tomosynthesis produces three-dimensional images which are intended to reveal the inner architecture of the breast free from the distortion typically caused by tissue shadowing or density. Planmed’s patented tomosynthesis method significantly improves image accuracy and allows even the smallest details to be captured with great precision. The latest research indicates that tomosynthesis increases the cancer detection rate and reduces the recall rate”, Moed concludes.

Planmed Clarity system is commercially available in most countries around the world.

For more information, please contact:
Jan Moed
Managing Director, Planmed Oy
Tel. 00 358 20 779 5387

jan.moed@planmed.com

Planmed Oy and Planmeca Group
Planmed Oy develops, manufactures, and markets advanced imaging equipment and accessories for mammography and orthopedic imaging. Planmed's extensive mammography product range covers digital and analog units and digital breast tomosynthesis (DBT) systems, stereotactic biopsy devices, and breast positioning systems for early detection of breast cancer. For orthopedic 3D imaging Planmed offers low dose extremity CT imaging for quicker, easier and more accurate diagnosis at point-of-care. Planmed Oy is strongly committed to R&D and design and the company exports more than 98% of its production to over 70 countries worldwide. Planmed Oy was established in 1989 and the company’s headquarters are located in Helsinki, Finland. Planmed Oy is part of Planmeca Group. The Group's turnover in 2016 was MEUR 730, employing nearly 2,700 people worldwide.

Subscribe

Documents & Links